STENTYS (FR0010949404 – STNT), a medical technology company
commercializing, in Europe, the world's first and only Self-Apposing®
stent to treat acute myocardial infarction (AMI), today announced
notification that the shares and securities now owned by Mr. Jacques
Séguin are all bound by lock-up agreement.
Following his stepping down as a Director and his nomination as a
Scientific Advisor to the Company, Prof. Jacques Séguin notified STENTYS
about his current shareholding. The Company decided to make this
As of 29 April 2013, Prof. Jacques Séguin only owns STENTYS securities
that are locked and cannot be sold until 31 December 2015, in accordance
with the Shareholder Agreement signed with Fonds Stratégique
d'Investissement (FSI) on 22 October 2012.
Upcoming financial results
STENTYS expects to publish its revenues for H1 2013 on 25 July 2013.
STENTYS is developing and commercializing innovative solutions for the
treatment of patients with acute myocardial infarction (AMI, or heart
attack) and complex coronary artery disease. STENTYS' Self-Apposing®
stents are designed to adapt to vessels with ambiguous or fluctuating
diameters, particularly in the post-infarction phase, in order to
prevent the malapposition problems associated with conventional stents.
In the APPOSITION III clinical trial, STENTYS stents demonstrated a very
low one year mortality rate among 1,000 high-risk AMI patients when
compared to recent studies with conventional stents. More
information is available at www.stentys.com.
STENTYS is listed on Comp. C of the NYSE Euronext Paris
FR0010949404 – Ticker: STNT
Stanislas Piot, +33 (0)1 44 53 99 42
Dusan Oresansky / Pierre Laurent, +33 (0)1 44 71 94 93
MacDougall Biomedical Communications
Charles Liles, 781 235 3060
Labaree, 650 339 7533